• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低剂量质子泵抑制剂(PPI)在日本PPI/抗生素联合治疗后根除幽门螺杆菌中的疗效。

Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.

作者信息

Kawai Takashi, Kawakami Kohei, Mikinori Kataoka, Takei Kazuo, Itoi Takao, Moriyasu Fuminori, Takagi Yuu, Aoki Tatsuya, Watanebe Kiyoshi, Matsumoto Yuushuke, Rimbara Emiko, Noguchi Norihisa, Sasatsu Masanori

机构信息

Endoscopy Center, Tokyo Medical University Hospital, Japan.

出版信息

Hepatogastroenterology. 2007 Mar;54(74):649-54.

PMID:17523342
Abstract

BACKGROUND/AIMS: In Japan, eradication regimens consisting of a proton pump inhibitor (PPI) + amoxicillin (AMPC) + clarithromycin (CAM) (PPI/AC) for 1 week have been conducted. In the present study, we assessed the eradication rates following treatment with low doses of various PPIs.

METHODOLOGY

135 patients were divided randomly into one of three 7-day regimens: (i) omeprazole (OPZ) 20 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (OAC); (ii) lansoprazole (LPZ) 30 mg + AMPC 1500 mg/day + CAM 600 mg/day (LAC); and (iii) rabeprazole (RPZ) 10mg/day + AMPC 1500 mg/ day + CAM 600 mg/day (RAC). The genetic polymorphism of CYP2C19 was also examined.

RESULTS

The eradication rates according to the treatment regimen were as follows: 69.9% (31/45) for OAC, 62.2% (28/45) for LAC, and 71.1% (32/45) for RPZ. No significant differences were found among the regimens. Moreover, eradication rates, according to CYP2C19 phenotype (homozygous extensive metabolizer (EM), heterozygous EM, and poor metabolizer) were: 68.6% (35/51), 77.4% (41/53), and 82.4% (14/17), respectively.

CONCLUSIONS

In PPI/AC therapy, the eradication rate for each low-dose PPI was 60-70%, which is low. Based on previous reports, it is considered that doses greater than 40 mg/day OPZ, 60 mg/day LPZ, and 20 mg/day RPZ are required.

摘要

背景/目的:在日本,已开展了为期1周的由质子泵抑制剂(PPI)+阿莫西林(AMPC)+克拉霉素(CAM)(PPI/AC)组成的根除方案。在本研究中,我们评估了使用低剂量各种PPI治疗后的根除率。

方法

135例患者被随机分为三种7天治疗方案中的一种:(i)奥美拉唑(OPZ)20mg/天+AMPC 1500mg/天+CAM 600mg/天(OAC);(ii)兰索拉唑(LPZ)30mg+AMPC 1500mg/天+CAM 600mg/天(LAC);以及(iii)雷贝拉唑(RPZ)10mg/天+AMPC 1500mg/天+CAM 600mg/天(RAC)。还检测了CYP2C19的基因多态性。

结果

根据治疗方案的根除率如下:OAC为69.9%(31/45),LAC为62.2%(28/45),RPZ为71.1%(32/45)。各方案之间未发现显著差异。此外,根据CYP2C19表型(纯合子广泛代谢型(EM)、杂合子EM和慢代谢型)的根除率分别为:68.6%(35/51)、77.4%(41/53)和82.4%(14/17)。

结论

在PPI/AC治疗中,每种低剂量PPI的根除率为60 - 70%,较低。根据既往报道,认为需要大于40mg/天的OPZ、60mg/天的LPZ和20mg/天的RPZ剂量。

相似文献

1
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.低剂量质子泵抑制剂(PPI)在日本PPI/抗生素联合治疗后根除幽门螺杆菌中的疗效。
Hepatogastroenterology. 2007 Mar;54(74):649-54.
2
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.关于CYP2C19基因型,质子泵抑制剂在幽门螺杆菌感染三联疗法中的比较:一项随机开放试验
J Gastroenterol Hepatol. 2002 Jul;17(7):748-53. doi: 10.1046/j.1440-1746.2002.02790.x.
3
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.CYP2C19基因分型差异对质子泵抑制剂、阿莫西林和克拉霉素三联疗法治疗幽门螺杆菌感染治愈率的影响。
Clin Pharmacol Ther. 2001 Mar;69(3):158-68. doi: 10.1067/mcp.2001.113959.
4
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.雷贝拉唑减量在质子泵抑制剂/抗生素联合疗法治疗幽门螺杆菌感染中的疗效:20毫克和40毫克雷贝拉唑与60毫克兰索拉唑的比较
Dig Dis Sci. 2000 Jan;45(1):77-82. doi: 10.1023/a:1005409310412.
5
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.在使用常规剂量质子泵抑制剂、克拉霉素和阿莫西林的三联疗法根除幽门螺杆菌失败后,采用高剂量雷贝拉唑/阿莫西林疗法作为二线治疗方案。
Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
6
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.雷贝拉唑三联疗法治疗幽门螺杆菌感染与CYP2C19基因分型的相关性
Korean J Gastroenterol. 2003 Dec;42(6):468-75.
7
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].[高剂量双重质子泵抑制剂/阿莫西林治疗标准三联质子泵抑制剂/阿莫西林/克拉霉素治疗失败后的幽门螺杆菌感染:CYP2C19基因多态性]
Nihon Rinsho. 2002 Feb;60 Suppl 2:439-44.
8
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.在日本,CYP2C19基因多态性对采用质子泵抑制剂(奥美拉唑或雷贝拉唑)、阿莫西林和克拉霉素三联疗法治疗幽门螺杆菌感染治愈率的影响。
Dig Liver Dis. 2001 Nov;33(8):671-5. doi: 10.1016/s1590-8658(01)80043-8.
9
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].[高剂量双重质子泵抑制剂/阿莫西林治疗常规标准三联质子泵抑制剂/阿莫西林/克拉霉素治疗失败后的幽门螺杆菌感染]
Nihon Rinsho. 2005 Nov;63 Suppl 11:438-41.
10
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.CYP2C19基因多态性对质子泵抑制剂一线双联和三联疗法中幽门螺杆菌根除率的影响:一项荟萃分析
Am J Gastroenterol. 2006 Jul;101(7):1467-75. doi: 10.1111/j.1572-0241.2006.00717.x.

引用本文的文献

1
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.通过临床CYP2C19基因分型提高幽门螺杆菌根除率。
Nagoya J Med Sci. 2011 Feb;73(1-2):25-31.